Chosa Oncology (previously RhoVac) is a Danish biotech focused on the development of iCIP, a technology consisting of a cisplatin drug response predictor and a liposomal formulation of conventional cisplatin. iCIP has demonstrated encouraging clinical proof of concept from a Phase IIb study in breast cancer patients and Chosa is now looking for strategic partnerships to progress the clinical development of the technology.
Healthcare |
Update
Healthcare |
Update
Healthcare |
Outlook
Healthcare |
Update
Claus Frisenberg Pedersen
CFO
Neil Goldsmith
Chairman
Peter Buhl Jensen
CEO
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 150.0 | 48.5 | (43.1) |
Relative | 136.3 | 36.5 | (53.9) |
52 week high/low | SEK1.7/SEK0.3 |
Chosa Oncology is a Scandinavian biotech looking to progress the clinical development of its cisplatin-based technology, iCIP, which consists of two core technologies: an AI-powered drug response predictor (DRP) that aims to identify the patients most likely to respond to cisplatin treatment and LiPlaCis, a liposomal cisplatin formulation with potential to improve both the safety and efficacy of conventional cisplatin. iCIP has demonstrated encouraging clinical proof-of-concept data from a Phase IIb study in metastatic breast cancer (mBC) patients, where patients with higher DRP scores were found to respond more effectively to LiPlaCis compared to those with lower DRP scores. In our view, iCIP is likely to interest pharmaceutical companies investigating novel cisplatin combination treatments. Chosa is looking to identify and secure strategic partnerships or buyers to advance iCIP into follow-on clinical studies.